Seda Yalova / Shutterstock.com
2 May 2024NewsBiotechnologyMarisa Woutersen

BioNTech’s patent counsel on fostering groundbreaking innovation

Ahead of her panel discussion at LSPN North America, Kady Bruce shares insights into her role and how she ensures innovations meet the criteria of novelty and nonobviousness.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 April 2024   New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.
Big Pharma
21 March 2024   US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

More on this story

Americas
26 April 2024   New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.
Big Pharma
21 March 2024   US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

More on this story

Americas
26 April 2024   New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.
Big Pharma
21 March 2024   US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.